
SFA Therapeutics Reports Promising Phase 1b Results for Oral Psoriasis Treatment
JENKINTOWN, PA — SFA Therapeutics, Inc. has announced encouraging results from its Phase 1b clinical trial of SFA-002, an oral drug candidate aimed at treating mild-to-moderate psoriasis. The study demonstrated both …
SFA Therapeutics Reports Promising Phase 1b Results for Oral Psoriasis Treatment Read More